|
Silence Therapeutics (AIM:SLN〔(【引用サイトリンク】url=http://www.google.co.uk/finance?q=LON:SLN )〕) is a biotechnology company that develops gene therapeutic technology based on RNA interference (RNAi). They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters based at 1 Lyric Square, London. ==Profile== The targeting, delivery and ongoing structural modification of sequences are the three platforms for Silence Therapeutics’s RNAi therapeutic development. These three platforms are: * proprietary delivery using nanoparticles and lipoplex technology * proprietary siRNA sequences complied using bioinformatics algorithms and scientific research * development of siRNA structural features Silence Therapeutics develops these structural modifications using three exclusive licences from the University of Massachusetts Amherst. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Silence Therapeutics」の詳細全文を読む スポンサード リンク
|